Blueprint Medicines (BPMC) to Release Quarterly Earnings on Thursday

Blueprint Medicines (NASDAQ:BPMC) will be releasing its earnings data before the market opens on Thursday, April 25th. Analysts expect Blueprint Medicines to post earnings of ($1.65) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings data on Thursday, February 15th. The biotechnology company reported ($1.82) EPS for the quarter, topping the consensus estimate of ($2.04) by $0.22. Blueprint Medicines had a negative net margin of 203.30% and a negative return on equity of 191.56%. The firm had revenue of $71.96 million during the quarter, compared to analyst estimates of $67.34 million. During the same quarter in the previous year, the business posted ($2.65) EPS. Blueprint Medicines’s revenue was up 85.5% on a year-over-year basis. On average, analysts expect Blueprint Medicines to post $-5 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Blueprint Medicines Trading Up 1.9 %

Shares of Blueprint Medicines stock opened at $92.29 on Wednesday. The company has a current ratio of 3.76, a quick ratio of 3.66 and a debt-to-equity ratio of 1.60. Blueprint Medicines has a 12-month low of $43.89 and a 12-month high of $101.00. The firm has a market capitalization of $5.65 billion, a price-to-earnings ratio of -11.04 and a beta of 0.63. The firm’s 50 day simple moving average is $90.36 and its two-hundred day simple moving average is $78.32.

Insider Buying and Selling at Blueprint Medicines

In other news, insider Christopher K. Murray sold 5,000 shares of the company’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $100.00, for a total transaction of $500,000.00. Following the completion of the transaction, the insider now owns 24,495 shares of the company’s stock, valued at approximately $2,449,500. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, insider Christopher K. Murray sold 5,000 shares of the stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $100.00, for a total transaction of $500,000.00. Following the completion of the sale, the insider now owns 24,495 shares of the company’s stock, valued at approximately $2,449,500. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Jeffrey W. Albers sold 25,073 shares of the stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $87.28, for a total transaction of $2,188,371.44. Following the sale, the director now directly owns 176,050 shares of the company’s stock, valued at approximately $15,365,644. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 117,289 shares of company stock worth $10,361,913. Corporate insiders own 3.88% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $97.00 price objective on shares of Blueprint Medicines in a report on Monday, February 26th. Wedbush reaffirmed an “outperform” rating and issued a $97.00 price objective on shares of Blueprint Medicines in a report on Monday, February 5th. Stifel Nicolaus upped their price objective on shares of Blueprint Medicines from $95.00 to $97.00 and gave the company a “buy” rating in a report on Tuesday, January 9th. Barclays upped their price objective on shares of Blueprint Medicines from $58.00 to $70.00 and gave the company an “equal weight” rating in a report on Tuesday, February 13th. Finally, JMP Securities reissued a “market outperform” rating and set a $114.00 price target on shares of Blueprint Medicines in a report on Wednesday, April 10th. Four equities research analysts have rated the stock with a sell rating, two have given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $85.43.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.